EUVIMEDEUVIMED entdecken
Crossref

Prime editing of human hematopoietic stem cells for correction of GATA2 deficiency

Jonas H Wolff iD, Thomas W Skov iD, Sofie R Dorset, Janni Sjelborg iD, Sujan Ravendran iD, Anne Louise S Revenfeld iD, Didde Haslund iD, Anaïs Marie Møller iD, Mette Holm iD, Martin K Thomsen iD, Trine H Mogensen iD, Bjarne K Møller iD und 2 weitere

Science Translational Medicine · 2026

DOI: 10.1126/scitranslmed.aec7031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Science Translational Medicine, 2026. Verfasst von Jonas H Wolff und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedicine, Aarhus University, Aarhus, Denmark. Hauptthemen laut MEDLINE: Hematopoietic Stem Cells, Gene Editing, GATA2 Deficiency, GATA2 Transcription Factor. Die Arbeit nennt 95 Literaturangaben. Gefördert von: Innovationsfonden, Carlsbergfondet, Novo Nordisk Fonden.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

GATA2 (GATA binding protein 2) deficiency is a severe immunodeficiency caused by heterozygous variants in the gene encoding the transcription factor GATA2. Ex vivo gene editing of a patient’s own CD34 + hematopoietic stem and progenitor cells (HSPCs) could provide curative treatment. However, current methods that rely on nuclease-dependent editing face considerable challenges, including off-target effects, genotoxicity, and reduced engraftment potential. Here, we report the development of an efficient gene editing therapy for GATA2 deficiency using prime editing with a favorable safety profile in terms of off-target effects and genotoxicity. We used prime editing to correct a GATA2 c.956_962del variant in patient-derived CD34 + HSPCs, reaching up to 70% prime editing efficiency and an increase in functional GATA2 alleles from 50 to 77%. We demonstrate that prime-edited patient HSPCs showed increased engraftment potential compared with untreated cells and detected limited on-target genotoxicity and no off-target editing at the top 20 predicted sites. Short prestimulation of CD34 + HSPCs supported efficient prime editing while preserving stemness, mitigating p53 activation, and increasing multilineage engraftment. We report PASSIGE (prime editing–assisted site-specific integrase gene editing) in CD34 + HSPCs, developing a more broadly applicable, double-strand break–independent complementary DNA insertion strategy with the potential to address a large proportion of alleles causing GATA2 deficiency. Together, our results demonstrate the preclinical development of prime editing–based therapies for GATA2 deficiency in CD34 + HSPCs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem CellsGene EditingGATA2 DeficiencyGATA2 Transcription FactorHumansAntigens, CD34AnimalsHematopoietic Stem Cell TransplantationBase Sequence

Substanzen

GATA2 Transcription FactorAntigens, CD34GATA2 protein, human

Autor:innen und Institutionen

  • Department of Biomedicine, Aarhus University, Aarhus, Denmark.
  • Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Pediatrics and Adolescent Medicine, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Clinical Medicine, Aarhus University Hospital, Aarhus, Denmark.
  • Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark.

ORCID-Profile: Jonas H Wolff, Thomas W Skov, Janni Sjelborg, Sujan Ravendran, Anne Louise S Revenfeld, Didde Haslund, Anaïs Marie Møller, Mette Holm, Martin K Thomsen, Trine H Mogensen, Bjarne K Møller, Rasmus O Bak, Jacob Giehm Mikkelsen

Förderung

  • Innovationsfonden
  • Carlsbergfondet
  • Novo Nordisk Fonden
  • the Danish National Research Foundation
  • Independent Research Fund Denmark

Zitieren

APA

Wolff, J. H., Skov, T. W., Dorset, S. R., Sjelborg, J., Ravendran, S., Revenfeld, A. L. S., Haslund, D., Møller, A. M., Holm, M., Thomsen, M. K., Mogensen, T. H., Møller, B. K., Bak, R. O., & Mikkelsen, J. G. (2026). Prime editing of human hematopoietic stem cells for correction of GATA2 deficiency. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.aec7031

Vancouver

Wolff JH, Skov TW, Dorset SR, Sjelborg J, Ravendran S, Revenfeld ALS, et al. Prime editing of human hematopoietic stem cells for correction of GATA2 deficiency. Science Translational Medicine. 2026. doi:10.1126/scitranslmed.aec7031

BibTeX
@article{Wolff2026,
  author = {Wolff, Jonas H and Skov, Thomas W and Dorset, Sofie R and Sjelborg, Janni and Ravendran, Sujan and Revenfeld, Anne Louise S and Haslund, Didde and Møller, Anaïs Marie and Holm, Mette and Thomsen, Martin K and Mogensen, Trine H and Møller, Bjarne K and Bak, Rasmus O and Mikkelsen, Jacob Giehm},
  title = {Prime editing of human hematopoietic stem cells for correction of GATA2 deficiency},
  journal = {Science Translational Medicine},
  year = {2026},
  doi = {10.1126/scitranslmed.aec7031}
}
Kostenlos starten →